Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma
Status:
Completed
Trial end date:
2020-03-02
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety, tolerability, and identify the recommended
doses of single agent CJM112, and of CJM112 or LCL161 in combination with PDR001, in patients
with relapsed and/or refractory multiple myeloma.